Ultragenyx Stock Crashes 42% on Failed Trial Data; Class Action Lawsuit Deadline Looms
Ultragenyx stock crashes 42% after disclosing failed Phase 3 trial for setrusumab; investors with losses exceeding $100,000 have until April 6, 2026 to file lead plaintiff applications in class action lawsuit.
RAREsecurities fraudclass action lawsuit